Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 2Other hematologic neoplasm 2Lymphoid 2Myeloid 1

Conditions

Myelodysplastic Syndromes 26Leukemia 21Lymphoma 17Leukemia, Myeloid, Acute 17Hodgkin Disease 16Multiple Myeloma 15Myeloproliferative Disorders 14Precursor Cell Lymphoblastic Leukemia-Lymphoma 13Lymphoma, Non-Hodgkin 12Leukemia, Lymphocytic, Chronic, B-Cell 11Congenital Abnormalities 10Lymphoma, Mantle-Cell 8Leukemia, Myeloid, Chronic-Phase 8Leukemia, Myelogenous, Chronic, BCR-ABL Positive 8Neoplasms, Plasma Cell 7Myelodysplastic-Myeloproliferative Diseases 7Lymphoma, Large-Cell, Immunoblastic 7Lymphoma, Large B-Cell, Diffuse 7Lymphoma, Follicular 7Lymphoma, B-Cell, Marginal Zone 7Burkitt Lymphoma 7Primary Myelofibrosis 6Leukemia, Myelomonocytic, Chronic 6Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 6Leukemia, Myeloid, Accelerated Phase 6Blast Crisis 6Anemia, Aplastic 6Graft vs Host Disease 5Waldenstrom Macroglobulinemia 4Recurrence 4

Interventions

fludarabine 2Tacrolimus 2fludarabine phosphate 1Whole-Body Irradiation 1Stem Cell Transplantation 1Mycophenolic Acid 1Cyclophosphamide 1Busulfan 1Alemtuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Paraproteinemias × Alemtuzumab × Myeloid × Clear all
NCT00579111 2016-05-04

Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB)

Baylor College of Medicine

Phase 1/2 Terminated
4 enrolled 8 charts
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Hematologic Diseases, Lymphoproliferative Disorders, Multiple Myeloma, Myeloproliferative Disorders, Paraproteinemias, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡